Literature DB >> 17019519

Menstrual cycle lengths and bone mineral density: a cross-sectional, population-based study in rural Chinese women ages 30-49 years.

F Ouyang1, X Wang, L Arguelles, L L Rosul, S A Venners, C Chen, Y-H Hsu, H Terwedow, D Wu, G Tang, J Yang, H Xing, T Zang, B Wang, X Xu.   

Abstract

INTRODUCTION: The menstrual cycle involves periodic fluctuations in estrogen and progesterone levels. Longer cycles have been associated with longer follicular phase, delayed estrogen peak and a lower mean oestradiol level of the entire cycle.
METHODS: We hypothesized that prolonged menstrual cycle length is associated with decreased bone mineral density (BMD) in a population of pre- and perimenopausal women. This population-based cross-sectional study was conducted in rural Anhui province, China. It includes 4,771 women, aged 30 to 49 years, who did not smoke or drink alcohol, and did not use oral contraceptives or breastfeed during the previous year. Dual-energy X-ray absorptionometry (DEXA) BMD measurements were taken at four skeletal sites: whole body, total hip, femoral neck and lumbar spine. Menstrual cycle characteristics (polymenorrhea, short normal, long normal, oligomenorrhea, 90-day amenorrhea, irregular cycle) in the prior year were assessed by questionnaire.
RESULTS: Prolonged menstrual cycle was consistently associated with decreased BMD at whole body, total hip, and femoral neck in both age 30-39, and age 40-49 stratum (p(trend)<0.05). Prolonged menstrual cycle was also associated with decreased lumbar spine BMD for women aged 40-49 (p(trend)<0.05). Among women with normal cycles aged 30-39, menstrual cycle length in the previous year was inversely associated with whole-body BMD (p<0.05). Women with 90-day amenorrhea had significantly lower mean total hip and femoral neck BMD relative to women with short normal cycles in the 30-39 age group; and had significantly lower whole body and total hip BMD relative to short normal cycles in the 40-49 age group. BMD in polymenorrheic women did not differ from BMD in women with short normal cycles at any of the skeletal sites.
CONCLUSIONS: We conclude that prolonged menstrual cycle length is associated with decreased BMD in pre- and perimenopausal women in this population.

Entities:  

Mesh:

Year:  2006        PMID: 17019519     DOI: 10.1007/s00198-006-0210-2

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  41 in total

1.  Characterization of perimenopausal bone loss: a prospective study.

Authors:  R Recker; J Lappe; K Davies; R Heaney
Journal:  J Bone Miner Res       Date:  2000-10       Impact factor: 6.741

2.  Bone metabolism during the perimenopausal transition: a prospective study.

Authors:  Vanadin Seifert-Klauss; Judith E Mueller; Peter Luppa; Reiner Probst; Jennifer Wilker; Cornelia Höss; Thomas Treumann; Christian Kastner; Kurt Ulm
Journal:  Maturitas       Date:  2002-01-30       Impact factor: 4.342

Review 3.  Perimenopause: the complex endocrinology of the menopausal transition.

Authors:  J C Prior
Journal:  Endocr Rev       Date:  1998-08       Impact factor: 19.871

Review 4.  The normal menopause transition: an overview.

Authors:  S M McKinlay
Journal:  Maturitas       Date:  1996-03       Impact factor: 4.342

5.  Bone health is not affected by luteal phase abnormalities and decreased ovarian progesterone production in female runners.

Authors:  M J De Souza; B E Miller; L C Sequenzia; A A Luciano; S Ulreich; S Stier; K Prestwood; B L Lasley
Journal:  J Clin Endocrinol Metab       Date:  1997-09       Impact factor: 5.958

6.  Decreased bone density in adolescent girls with anorexia nervosa.

Authors:  L K Bachrach; D Guido; D Katzman; I F Litt; R Marcus
Journal:  Pediatrics       Date:  1990-09       Impact factor: 7.124

7.  Pre-existing fractures and bone mass predict vertebral fracture incidence in women.

Authors:  P D Ross; J W Davis; R S Epstein; R D Wasnich
Journal:  Ann Intern Med       Date:  1991-06-01       Impact factor: 25.391

8.  Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.

Authors:  S R Cummings; D M Black; M C Nevitt; W Browner; J Cauley; K Ensrud; H K Genant; L Palermo; J Scott; T M Vogt
Journal:  Lancet       Date:  1993-01-09       Impact factor: 79.321

9.  Alcohol intake as a risk factor for fracture.

Authors:  John A Kanis; Helena Johansson; Olof Johnell; Anders Oden; Chris De Laet; John A Eisman; Huibert Pols; Alan Tenenhouse
Journal:  Osteoporos Int       Date:  2004-09-29       Impact factor: 4.507

10.  Low bone mineral density at axial and appendicular sites in amenorrheic athletes.

Authors:  K H Myburgh; L K Bachrach; B Lewis; K Kent; R Marcus
Journal:  Med Sci Sports Exerc       Date:  1993-11       Impact factor: 5.411

View more
  4 in total

1.  Non-reproductive Effects of Anovulation: Bone Metabolism in the Luteal Phase of Premenopausal Women Differs between Ovulatory and Anovulatory Cycles.

Authors:  B Niethammer; C Körner; M Schmidmayr; P B Luppa; V R Seifert-Klauss
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-12       Impact factor: 2.915

2.  Progesterone and bone: actions promoting bone health in women.

Authors:  Vanadin Seifert-Klauss; Jerilynn C Prior
Journal:  J Osteoporos       Date:  2010-10-31

3.  Adult Premenopausal Bone Health Related to Reproductive Characteristics-Population-Based Data from the Canadian Multicentre Osteoporosis Study (CaMos).

Authors:  Azita Goshtasebi; Claudie Berger; Susan I Barr; Christopher S Kovacs; Tanveer Towheed; K Shawn Davison; Jerilynn C Prior
Journal:  Int J Environ Res Public Health       Date:  2018-05-18       Impact factor: 3.390

4.  Does Molimina Indicate Ovulation? Prospective Data in a Hormonally Documented Single-Cycle in Spontaneously Menstruating Women.

Authors:  Jerilynn C Prior; Chiaki Konishi; Christine L Hitchcock; Elaine Kingwell; Patti Janssen; Anthony P Cheung; Nichole Fairbrother; Azita Goshtasebi
Journal:  Int J Environ Res Public Health       Date:  2018-05-18       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.